Monopar Therapeutics Inc stock analysis
Want to see MNPR full AI Analyst Report?
Monopar Therapeutics Inc (MNPR) Stock Price & Analysis
MNPR Stock Chart & Stats
- Day’s Range
- $68.69 - $72.80
- 52-Week Range
- $50.07 - $124.82
- Previous Close
- $70.75
- Volume
- N/A
- Average Volume (3M)
- 146.78K
- Market Cap
- $476.34M
- Enterprise Value
- $552.84M
- Total Cash (Recent Filing)
- $129.45M
- Total Debt (Recent Filing)
- $357.26K
- Price to Earnings (P/E)
- ―
- Beta
- 1.54
- Next Earnings
- Mar 25, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage limits refinancing and solvency pressure, which is valuable for a pre-revenue biotechnology company facing uncertain development timelines. A comparatively under-levered balance sheet preserves flexibility to fund research, absorb setbacks, and pursue financing without adding substantial debt-service obligations.
Balance Sheet Flexibility
A meaningful equity and asset base relative to debt provides financial capacity while the company advances drug candidates toward clinical milestones. This structure can support continued development and reduce dependence on debt markets, although it does not remove the need for future capital.
Development-Focused Pipeline
Internal development keeps the company focused on advancing targeted therapeutics for cancer and other serious diseases rather than maintaining a broad commercial operating structure. Progress through preclinical and clinical stages could create strategic value if candidates demonstrate efficacy and reach later development milestones.
Bears Say
No Product Revenue
The absence of revenue leaves the company without an operating base to absorb research and corporate costs, making financial results dependent on spending levels and capital access. Until a candidate is commercialized or produces licensing income, earnings visibility and the ability to self-fund development remain weak.
Accelerating Cash Burn
Persistent negative cash generation reduces the funds available for ongoing operations and clinical development, while the sharper TTM burn indicates that funding needs are increasing. Continued consumption of cash can force additional capital raising and may constrain the pace or scope of future programs.
Deepening Losses
Persistent and substantially larger TTM losses indicate that expenses are rising without a revenue base to offset them. This weak profitability profile increases dependence on external funding, reduces tolerance for clinical or regulatory setbacks, and makes future earnings highly dependent on successful development outcomes.
Monopar Therapeutics Inc News
MNPR FAQ
What was Monopar Therapeutics Inc’s price range in the past 12 months?
What is Monopar Therapeutics Inc’s market cap?
When is Monopar Therapeutics Inc’s upcoming earnings report date?
How were Monopar Therapeutics Inc’s earnings last quarter?
Is Monopar Therapeutics Inc overvalued?
Does Monopar Therapeutics Inc pay dividends?
What is Monopar Therapeutics Inc’s EPS estimate?
How many shares outstanding does Monopar Therapeutics Inc have?
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
What is the TipRanks Smart Score and how is it calculated?
Monopar Therapeutics Inc Stock Smart Score
Company Description
Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Chandler D. Robinson
- Employees
- 22
- Website
- www.monopartx.com
- Address
- 1000 Skokie Boulevard, Wilmette, IL, 60091, US
Monopar Therapeutics Inc (MNPR) Earnings & Revenues
MNPR Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 15 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 12 |












